Kevin Kuntz, Ph.D.
Chief Drug Development Officer
Dr. Kuntz is an experienced and successful drug discovery scientist with over 20 years of experience, including extensive research in kinase inhibitors and protein methyltransferase inhibitors. Prior to joining Ribon, he was Head of Chemistry at Epizyme. While at Epizyme, Dr. Kuntz invented tazemetostat (Tazverik®), a small molecule approved by the US FDA in 2020 to treat epithelioid sarcoma and follicular lymphoma. Earlier in his career, he was a researcher at GlaxoSmithKline and Avila Therapeutics. While at GSK, Dr. Kuntz was a co-inventor of dabrafenib, a BRAF inhibitor approved to treat melanoma.
Dr. Kuntz received his Ph.D. in Organic Chemistry at Boston College and B.S. in Chemistry at Trinity University.